---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045310"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:35:07.567287+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q1 net loss $37.4M; revenue down 45% YoY; raises adjusted EBITDA guidance to >$105M

## Summary
- Total revenue of $41.1M vs $74.9M in Q1 2024, down 45% YoY.
- GAAP net loss $37.4M ($0.23 loss per share) vs $4.2M loss a year ago.
- Adjusted EBITDA guidance raised to >$105M for FY 2025; on track to meet full-year guidance.
- LINZESS prescription demand grew 8% YoY in Q1 2025, in line with expectations.
- Company is exploring strategic alternatives to maximize stockholder value.

## SEC filing metadata
- accession: 0001104659-25-045310
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/0001104659-25-045310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/tm2514185d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045310
- JSON: https://secwatch.observer/filing/0001104659-25-045310.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.